ArticleFrontiers in cellular and infection microbiology2026
Microbiome-based probiotic intervention to reduce chemotherapy-induced gastrointestinal toxicity.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chemotherapy is one of the primary treatment options for cancer; however, its gastrointestinal toxicity and disruption of gut microbial homeostasis can adversely affect patient health and treatment outcomes. This study investigated chemotherapy-induced alterations in the gut microbiome and evaluated the effects of probiotic supplementation on microbial diversity, gastrointestinal toxicity, and treatment response in cancer patients. Methods: The probiotic strain was isolated from a commercial formulation and identified as Lactobacillus casei using biochemical characterization and 16S rRNA gene sequencing. Its secreted metabolites were characterized using Fourier-transform infrared spectroscopy (FTIR), gas chromatography-mass spectrometry (GC-MS), high-performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR) spectroscopy. A total of 150 patients receiving platinum-based chemotherapy were enrolled and divided into control and probiotic intervention groups. Fecal samples were collected before and after chemotherapy and subjected to 16S rRNA sequencing to assess microbial diversity and taxonomic composition. Results: Chemotherapy induced significant gut microbial dysbiosis, characterized by reduced alpha diversity, decreased abundance of beneficial bacteria, including Lactobacillus, Bifidobacterium, and Faecalibacterium, and increased abundance of opportunistic pathogens such as Escherichia-Shigella and Klebsiella. In contrast, probiotic-treated patients maintained a relatively balanced gut microbiota and exhibited less pronounced dysbiosis after chemotherapy. Gastrointestinal complications were also reduced following probiotic supplementation. Overall gastrointestinal toxicity was observed in 85% of control patients compared with 65% of probiotic-treated patients, while diarrhea occurred in 60% and 35%, respectively. Grade 3-4 gastrointestinal toxicity was reported in 40% of control patients compared with 20% of probiotic-treated patients. Probiotic supplementation was additionally associated with lower incidence and severity of mucositis, nausea, and vomiting. Chemotherapy responders exhibited a more favorable microbial profile with greater abundance of beneficial commensal bacteria than non-responders. Receiver operating characteristic analysis identified microbial taxa as potential predictors of chemotherapy outcomes, with AUC values of 0.81 for Bacteroides ovatus, 0.78 for Faecalibacterium prausnitzii, and 0.86 for the combined response model. The combined microbial model achieved an AUC of 0.88 for predicting severe gastrointestinal toxicity. Discussion: Overall, probiotic supplementation may help preserve intestinal microbial homeostasis, reduce chemotherapy-associated gastrointestinal toxicity, and support improved treatment outcomes in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.